A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation

Cancer vaccination holds great promise for cancer treatment, but its effectiveness is hindered by suboptimal activation of CD8+ cytotoxic T lymphocytes, which are potent effectors to mediate anti-tumor immune responses. A possible solution is to switch antigen-presenting cells to present tumor antig...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Daping Xie, Congwei Han, Chonghao Chen, Zhencheng Liao, Senio Campos de Souza, Yiming Niu, João F. Mano, Lei Dong, Chunming Wang
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	KeAi Communications Co., Ltd. 2024-07-01
Ráidu:	Bioactive Materials
Fáttát:	Scaffold vaccine TLR2 agonist Polysaccharide Reactive oxygen species Cross-presentation
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2452199X24001269
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!